We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

A Rapid AI-based Screening Test for Prostate Cancer Biomarkers in Urine

By LabMedica International staff writers
Posted on 01 Feb 2021
Print article
Image: The 20-minute AI analysis detected prostate cancer in urine samples from 76 patients with greater than 99% accuracy (Photo courtesy of Korea Institute of Science and Technology)
Image: The 20-minute AI analysis detected prostate cancer in urine samples from 76 patients with greater than 99% accuracy (Photo courtesy of Korea Institute of Science and Technology)
A team of Korean investigators developed a highly accurate rapid technique for diagnosing prostate cancer based on AI (artificial intelligence) monitoring of urinary biomarkers.

Screening for prostate cancer generally relies on the serum prostate-specific antigen (PSA) test, which unfortunately generates a high rate of false positive results (up to 80%). This generates a large number of unnecessary biopsies with resultant unpleasant side effects, such as bleeding and pain. Considering how often the PSA test is used, there is a critical unmet need for a precision screening method for diagnosis of prostate cancer.

Toward this end, investigators at the Korea Institute of Science and Technology (Seoul) and their collaborators developed a technique for diagnosing the disease from urine by utilizing an electrical-signal-based ultrasensitive biosensor. The semiconductor sensor system was capable of simultaneously measuring trace amounts of four selected cancer factors in urine. The correlation of clinical state with the sensing signals from urinary biomarkers was analyzed by two common machine learning algorithms. As the number of biomarkers was increased, both algorithms provided a monotonic increase in screening performance.

When applied to urine samples from patients, the 20-minute AI analysis successfully detected 76 urinary samples with greater than 99% accuracy.

Senior author Dr. Kwan Hyi Lee, a principal research scientist at the Korea Institute of Science and Technology, said, "This research developed a smart biosensor that can rapidly diagnose prostate cancer with almost 100% accuracy only through a urine test, and it can be further utilized in the precise diagnoses of other cancers using a urine test."

The AI-based assay for diagnosis of prostate cancer was described in the December 9, 2020, online edition of the journal ACS Nano.

Related Links:
Korea Institute of Science and Technology

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more

Pathology

view channel
Image: The OvaCis Rapid Test discriminates benign from malignant epithelial ovarian cysts (Photo courtesy of INEX)

Intra-Operative POC Device Distinguishes Between Benign and Malignant Ovarian Cysts within 15 Minutes

Ovarian cysts represent a significant health issue for women globally, with up to 10% experiencing this condition at some point in their lives. These cysts form when fluid collects within a thin membrane... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.